Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alpha 21** appears to be an Ayurvedic product name marketed by Alpha Arogya rather than a well-characterized pharmaceutical active ingredient. Publicly accessible evidence indicates that the product was offered for sale in the United States with disease-treatment claims, including COVID-19-related claims cited by the FDA, but the available sources do not clearly identify a validated active ingredient, mechanism of action, dosage form, route, manufacturer labeling details, or a conventional drug-development program. On the basis of the available evidence, it is best treated as a branded, non-specific traditional medicine product with insufficient publicly verifiable pharmacologic characterization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alpha 21.